Natco Pharma posts Rs 715.3 crore of Profit after tax for year ended March 31st, 2023
The profit for the fourth quarter, on a consolidated basis was INR 275.8 Crore, as against a loss of INR 50.5 Crore last year fourth quarter.
Hyderabad: Hyderabad-based NATCO Pharma Limited has recorded consolidated total revenue of INR 2811.7 Crore for the year ended on 31st March, 2023, as against INR 2043.8 Crore for the last year, reflecting 37.6% growth.
The net profit for the period, on a consolidated basis, was INR 715.3 Crore, as against INR 170.0 Crore last year. The increase in revenue and profits for the year was driven by business growth in the US market and growth in the company's subsidiaries in Canada & Brazil.
Natco Crop Health Division started off well with strong growth potential in ensuing years. For the fourth quarter (Q4) ended March 31st, 2023, the company recorded a net revenue of INR 926.9 Crore, on a consolidated basis, as against INR 610.6 Crore during Q4, FY 2022. The profit for the fourth quarter, on a consolidated basis was INR 275.8 Crore, as against a loss of INR 50.5 Crore last year fourth quarter.
Read also: Natco Pharma to set up subsidiary in Indonesia with investment of Rs 25 crore
Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). The company's focus is primarily on niche therapeutic areas and complex products. It markets and distributes products in over 40 countries. It sells FDF products in the United States, India, Europe and the rest of the world (“RoW”). Natco also operates in certain key geographies through its subsidiaries.
Natco Pharma is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.
Read also: Multiple Myeloma medicine: Natco Pharma unveils Pomalidomide under brand NAT-POMALIDOMIDE in Canada
